

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY-G
05 AUG 22

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P.			
2. Address <input type="checkbox"/> Check if different than previously reported 1333 New Hampshire Avenue, NW			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID
Donald R. Pongrace	202-887-4000		682-86
7. Client Name <input type="checkbox"/> Self Pfizer, Inc.			6. House ID 31784

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000
\$10,000 or more ⇒ \$ 100,000
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000
\$10,000 or more ⇒ \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.
 Method A. Reporting amounts using LDA definition
 Method B. Reporting amounts under section 6011 Internal Revenue Code
 Method C. Reporting amounts under section 162 Internal Revenue Code

Signature _____ Date August 15, 2005

0000430234

Registrant Name Akin, Gump, Strauss, Hauer & Feld, L.L.P. Client Name Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare Modernization Act (MMA) implementation issues, including Part D prescription drug benefit electronic prescribing; reimportation, including S. 2328 and S. 2493; and Medicare Part B drug payment developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues


17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House of Representatives
- U.S. Senate
- U.S. Department of Health & Human Services
- U.S. Department of the Interior
- U.S. Department of Justice
- Center for Medicare & Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

Name (bolded names are new lobbyists)	Covered Official Position (if applicable)
Smith W. Davis	
Gary A. Heimberg	
Jorge Lopez, Jr.	
Donald R. Pongrace	
Barney J. Skladany	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date August 15, 2005
Printed Name and Title Donald R. Pongrace, Partner

0000430235

